Expect Limited Use of IV Brexanolone (Zulresso) for Postpartum Depression
Intravenous brexanolone (Zulresso, zul-REH-soh) will make a splash as the first FDA-approved treatment for postpartum depression.
Brexanolone has a unique mechanism...it mimics the hormone allopregnanolone, which interacts with GABA receptors. This hormone abruptly dips around childbirth...possibly leading to major depression.
Brexanolone is given as a single 60-hour infusion. It starts to improve depression symptoms 24 to 48 hours after starting the infusion. In comparison, SSRIs take at least 1 to 2 weeks to start working.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote